13 terminated. 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Terminated 13 |
Follow Amyloidosis: new trials by email Literature Review of Amyloidosis trials Research Report on Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis daratumumab and pomalidomide - AL Amyloidosis | Phase 2 | Terminated | Fondazione IRCCS Policlinico San Matteo di Pavia | 27 | 2021-06-23 | 2025-02-20 |
| 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients Inotersen - Amyloidosis | Phase 2 | Terminated | Brigham and Women's Hospital | 31 | 2019-02-28 | 2026-02-20 |
| Open-Label Study of AG10 in Patients With Cardiomyopathy Acoramidis - Amyloid Cardiomyopathy | Phase 2 | Terminated | Eidos Therapeutics, a BridgeBio company | 47 | 2018-08-08 | 2026-10-14 |
| Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Propylene Glycol-Free Melphalan Hydrochloride - Amyloidosis; Systemic | Phase 2 | Terminated | Boston Medical Center | 27 | 2018-01-08 | 2023-05-24 |
| Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698 GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb) - Amyloidosis | Phase 2 | Terminated | GlaxoSmithKline | 7 | 2017-07-10 | 2019-10-16 |
| Renal AL Amyloid Involvement and NEOD001 NEOD001, Placebo - Amyloidosis | Phase 2 | Terminated | Tufts Medical Center | 12 | 2017-07-05 | 2020-09-09 |
| Study in Subjects With Light Chain (AL) Amyloidosis NEOD001 - AL Amyloidosis | Phase 2 | Terminated | Prothena Biosciences Ltd. | 80 | 2017-06-14 | 2019-03-26 |
| Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis NEOD001 - AL Amyloidosis | Phase 2 | Terminated | Prothena Biosciences Ltd. | 34 | 2016-02-01 | 2019-05-16 |
| Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis Idelalisib - Amyloidosis | Phase 2 | Terminated | John Mark Sloan | 1 | 2016-01-01 | 2017-09-21 |
| Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment Dexamethasone, Tandem autologous stem cell transplant, Cisplatin - Multiple Myeloma | Phase 2 | Terminated | University of Iowa | 19 | 2012-05-01 | 2017-06-14 |
| Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias), Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG - Primary Amyloidosis of Light Chain Type | Phase 2 | Terminated | Fondazione IRCCS Policlinico San Matteo di Pavia | 86 | 2012-01-01 | 2018-03-21 |
| HD Melphalan and SCT in Patients With IGDD or LCDD filgrastim, melphalan, Stem Cell Infusion - Multiple Myeloma | Phase 2 | Terminated | Boston Medical Center | 5 | 2006-10-01 | 2017-04-28 |
| 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis filgrastim, melphalan, autologous stem cell transplantation - Multiple Myeloma, Plasma Cell Neoplasm | Phase 2 | Terminated | Boston Medical Center | 12 | 2001-08-01 | 2017-01-27 |
Immunoglobulin Light-chain Amyloidosis (7) · Multiple Myeloma (3) · Alzheimer Disease (1) · Amyloid Neuropathies, Familial (1) · Cardiomyopathies (1) · Endocrine System Diseases (1) · Neoplasms, Plasma Cell (1) · Paraproteinemias (1) · Polyneuropathies (1)
Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13) · Proteostasis Deficiencies (13) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Plasma Cell (7) · Paraproteinemias (7) · Cardiovascular Diseases (4) · Blood Protein Disorders (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3)
Melphalan (4) · birtamimab (3) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Bortezomib (1) · Calcium Dobesilate (1) · Cisplatin (1) · Cyclophosphamide (1) · Dexamethasone (1) · Diuretics (1) · Doxorubicin (1) · Etoposide (1) · Inotersen (1) · Oligonucleotides, Antisense (1) · Thalidomide (1)
Boston Medical Center (3) · Fondazione IRCCS Policlinico San Matteo di Pavia (2) · Prothena Biosciences Ltd. (2) · Brigham and Women's Hospital (1) · Eidos Therapeutics, a BridgeBio company (1) · GlaxoSmithKline (1) · John Mark Sloan (1) · Tufts Medical Center (1) · University of Iowa (1)
United States (11) · Italy (3) · United Kingdom (2) · Australia (1) · Austria (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Spain (1)
Guido J Tricot, MD, PhD (1) · John M Sloan, MD (1) · Karen Quillen, MD (1) · Raymond Comenzo, MD (1) · Rodney Falk, MD (1) · Vaishali Sanchorawala, MD (1)
PMID 37607644, PMID 40216220, PMID 42389794
2016 (1), R01CA115399 (1)